Table 1.
Demographics and baseline characteristics of patients enrolled in ARTS
| Part A (n = 65) | Part B (n = 392) | |
|---|---|---|
| Males, n (%) | 52 (80.0) | 312 (79.6) |
| Mean age (range), years | 66.3 (42–85) | 72.1 (40–89) |
| Mean BMI (range), kg/m2 | 28.6 (21.5–41.4) | 28.8 (18.1–46.9) |
| Mean systolic blood pressure (range), mmHg | 133.8 (83–169) | 127.3 (81–180) |
| NYHA functional class, n (%) | ||
| II | 62 (95.4) | 320 (81.6) |
| III | 3 (4.6) | 72 (18.4) |
| Medical history, n (%) | ||
| Ischaemic heart disease | 24 (36.9) | 251 (64.0) |
| Atrial fibrillation | 24 (36.9) | 177 (45.2) |
| Congestive cardiomyopathy | 8 (12.3) | 36 (9.2) |
| Arterial hypertension | 28 (43.1) | 261 (66.6) |
| Diabetes mellitus | 9 (13.8) | 134 (34.2) |
| Treated with metformin | 5 (7.7) | 51 (13.0) |
| Concomitant medication, n (%) | ||
| Agents acting on renin–angiotensin system | 64 (98.5) | 372 (94.9) |
| Beta-blockers | 63 (96.9) | 366 (93.4) |
| Diuretics | 46 (70.8) | 349 (89.0) |
| Baseline laboratory values | ||
| Mean serum potassium ± SD, mmol/L | 4.23 ± 0.33 | 4.29 ± 0.42 |
| Median serum creatinine (range), mg/dL | 1.000 (0.70–1.30) | 1.400 (0.80–3.10) |
| Mean eGFR (MDRD) ± SD, mL/min/1.73 m2 | 69.1 ± 8.43 | 47.0 ± 10.0 |
| Geometric mean UACR (geometric SD), mg/g | 13.67 (3.20) | 21.33 (4.87) |
| Median BNP (range), pg/mL | – | 270.0 (10–6382) |
| Median NT-proBNP (range), pg/mL | – | 1381.45 (22.7–32 349.1) |
| Median serum aldosterone (range), pmol/L | – | 279.100 (<LLOQ–2557.70) |
The dash indicates data not recorded; BMI, body mass index; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; LLOQ, lower limit of quantification (for serum aldosterone, LLOQ = 7.35 pmol/L); MDRD, modification of diet in renal disease; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation; UACR, urinary albumin:creatinine ratio.